Brought to you by 
Artios Pharma closes £25mm Series A round
20 Sep 2017
Executive Summary
Newly launched cancer-focused biotech Artios Pharma Ltd. raised £25mm ($33.2mm) through its Series A round led by SV Life Sciences. Additional investors included Imperial Innovations (which took a 14.9% ownership stake with a £5.1mm investment), Merck Ventures, Arix Bioscience, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Artios Pharma closes £25mm Series A round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice